What are the differences and safety profiles between Monofer (ferric derisomaltose) and Ferric carboxymaltose (Ferinject)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Monofer (Ferric Derisomaltose) vs Ferric Carboxymaltose: Key Differences and Safety

Ferric derisomaltose (Monofer/FDI) has a significantly superior safety profile compared to ferric carboxymaltose (FCM), primarily due to dramatically lower rates of hypophosphatemia, and should be the preferred high-dose intravenous iron formulation when repeat dosing or risk factors for phosphate depletion are present. 1

Primary Safety Difference: Hypophosphatemia Risk

The most clinically significant difference between these formulations is the risk of hypophosphatemia:

  • FDI causes hypophosphatemia in only 7.9-8.1% of patients
  • FCM causes hypophosphatemia in 73.7-75.0% of patients 1
  • This represents an 8-fold higher risk with FCM (RR 8.37,95% CI 5.10-13.75) 2

Mechanism and Clinical Consequences

Both formulations can increase fibroblast growth factor-23 (FGF-23), which stimulates renal phosphate excretion, but FCM induces a much more pronounced FGF-23 response than FDI 3. This difference has serious clinical implications:

  • Severe hypophosphatemia (<1.0 mg/dL) occurs in 11.3% with FCM but is not observed with FDI 2
  • Persistent hypophosphatemia beyond 5-8 weeks is more frequent with FCM 2
  • Repeated FCM use can cause severe osteomalacia with bone pain, pseudofractures (Looser zones), and low-trauma fractures 3

Critical Pitfall: Hypophosphatemia symptoms (fatigue, malaise, muscle weakness) overlap with iron deficiency anemia symptoms, potentially masking the complication 4.

Dosing and Administration Differences

Ferric Derisomaltose (Monofer) 5

  • Concentration: 100 mg/mL
  • Maximum single dose: 2000 mg (only formulation FDA-labeled for total dose infusion)
  • Infusion time: ≤1000 mg over ≥15 minutes; >1000 mg over ≥30 minutes
  • Minimum infusion time: 20 minutes for any dose 5
  • Can deliver complete iron repletion in a single visit

Ferric Carboxymaltose 6, 7

  • Concentration: 50 mg/mL
  • Maximum single dose: 1000 mg
  • Infusion time: 200-500 mg over 6 minutes; 500-1000 mg over 15 minutes
  • US packaging: 750 mg vials requiring two doses 1 week apart (minimum 1500 mg or wastage of 500 mg) 7

Hypersensitivity Reactions

Both formulations have comparable low rates of severe hypersensitivity reactions (<1%) 3. These are typically complement activation-related pseudo-allergy (CARPA) reactions rather than true allergic responses 8.

Management Approach

  • Start infusions slowly and observe for several minutes 7
  • Do NOT treat minor infusion reactions with vasopressors or H1 blockers - this converts benign reactions into hemodynamically significant events 8
  • Most minor reactions resolve without intervention

Efficacy Comparison

Both formulations demonstrate equivalent efficacy for correcting iron deficiency anemia:

  • Similar hemoglobin increases
  • Comparable restoration of iron stores
  • Non-inferior outcomes in head-to-head trials 5

However, FDI shows additional benefits:

  • Greater improvement in fatigue scores 2
  • Higher quality-adjusted life years in economic analyses 2
  • Lower overall healthcare costs 2

Clinical Decision Algorithm

Choose FDI (Monofer) when:

  • Repeat infusions are anticipated
  • Patient has baseline low phosphate or risk factors for hypophosphatemia
  • Single-visit complete iron repletion is desired (up to 2000 mg)
  • Patient has conditions requiring phosphate monitoring (CKD, malabsorption, vitamin D deficiency)

FCM may be considered when:

  • Single dose only is planned
  • Patient has normal baseline phosphate
  • No risk factors for phosphate depletion exist
  • FDI is unavailable

Mandatory monitoring with FCM: Check serum phosphate at baseline and 4-8 weeks post-infusion in patients requiring repeat doses or with risk factors 4.

Populations at Highest Risk for FCM-Induced Hypophosphatemia

  • Patients requiring repeat infusions 7
  • Chronic kidney disease 4
  • Malabsorption syndromes
  • Vitamin D deficiency
  • Inflammatory bowel disease
  • Pregnancy and postpartum 4

Storage and Handling

Both formulations:

  • Store at room temperature (20-25°C)
  • Do not freeze
  • Once diluted in 0.9% sodium chloride, stable for up to 8 hours at room temperature 5

Contraindications

Both formulations are contraindicated in:

  • Known hypersensitivity to the specific formulation 5
  • Iron overload conditions 5

The evidence overwhelmingly supports FDI as the safer choice for most clinical scenarios, particularly when the dramatic difference in hypophosphatemia risk is considered alongside equivalent efficacy. 1, 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.